tiprankstipranks
Trending News
More News >

Y-mAbs Therapeutics price target lowered to $11 from $12 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $11 from $12 and keeps a Buy rating on the shares following the Q1 report.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1